Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine

被引:31
作者
Otani, K
Ishida, M
Kaneko, S
Mihara, K
Ohkubo, T
Osanai, T
Sugawara, K
机构
[1] HIROSAKI UNIV HOSP,DEPT PHARM,HIROSAKI,AOMORI 036,JAPAN
[2] GOSHOGAWARA CITY HOSP,DEPT PHARM,GOSHOGAWARA,JAPAN
关键词
carbamazepine; trazodone; m-chlorophenylpiperazine; plasma concentration; metabolism;
D O I
10.1097/00007691-199604000-00010
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine (m-CPP) were studied in six depressed patients treated with trazodone. The daily dose of trazodone was 150 mg in three cases and 300 mg in three cases. Carbamazepine, 400 mg/day, was coadministered for 4 weeks, and blood samples were taken before carbamazepine addition and at weekly intervals after the addition. Carbamazepine significantly (p < 0.01) decreased plasma concentrations of not only trazodone but also m-CPP at each week. On the average, plasma concentrations of trazodone and m-CPP at 4 weeks were 24 and 40% of the corresponding precarbamazepine values. This study thus suggests that carbamazepine coadministration decreases plasma concentrations of trazodone and m-CPP by inducing the metabolism of these compounds.
引用
收藏
页码:164 / 167
页数:4
相关论文
共 23 条
[1]   ANTICONVULSANT COTREATMENT MAY INCREASE TOXIC METABOLITES OF ANTIDEPRESSANTS AND OTHER PSYCHOTROPIC-DRUGS [J].
BALDESSARINI, RJ ;
TEICHER, MH ;
CASSIDY, JW ;
STEIN, MH .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1988, 8 (05) :381-382
[2]   CLINICAL PHARMACOKINETICS AND PHARMACOLOGICAL EFFECTS OF CARBAMAZEPINE AND CARBAMAZEPINE-10,11-EPOXIDE - AN UPDATE [J].
BERTILSSON, L ;
TOMSON, T .
CLINICAL PHARMACOKINETICS, 1986, 11 (03) :177-198
[3]   THE INFLUENCE OF ENVIRONMENTAL AND GENETIC-FACTORS ON CYP2D6, CYP1A2 AND UDP-GLUCURONOSYLTRANSFERASES IN MAN USING SPARTEINE, CAFFEINE, AND PARACETAMOL AS PROBES [J].
BOCK, KW ;
SCHRENK, D ;
FORSTER, A ;
GRIESE, EU ;
MORIKE, K ;
BROCKMEIER, D ;
EICHELBAUM, M .
PHARMACOGENETICS, 1994, 4 (04) :209-218
[4]   CONCOMITANT INTAKE OF NORTRIPTYLINE AND CARBAMAZEPINE [J].
BROSEN, K ;
KRAGHSORENSEN, P .
THERAPEUTIC DRUG MONITORING, 1993, 15 (03) :258-260
[5]  
BROWN CS, 1990, J CLIN PSYCHOPHARM, V10, P359
[6]   EFFECTS OF VARIOUS FACTORS ON STEADY-STATE PLASMA-CONCENTRATIONS OF TRAZODONE AND ITS ACTIVE METABOLITE M-CHLOROPHENYLPIPERAZINE [J].
ISHIDA, M ;
OTANI, K ;
KANEKO, S ;
OHKUBO, T ;
OSANAI, T ;
YASUI, N ;
MIHARA, K ;
HIGUCHI, H ;
SUGAWARA, K .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 (03) :143-146
[7]  
JAUCH R, 1976, ARZNEIMITTEL-FORSCH, V26, P2084
[8]   THE USE OF THERAPEUTIC DRUG-MONITORING DATA TO DOCUMENT KINETIC DRUG-INTERACTIONS - AN EXAMPLE WITH AMITRIPTYLINE AND NORTRIPTYLINE [J].
JERLING, M ;
BERTILSSON, L ;
SJOQVIST, F .
THERAPEUTIC DRUG MONITORING, 1994, 16 (01) :1-12
[9]   META-CHLOROPHENYLPIPERAZINE AS A PROBE OF SEROTONIN FUNCTION [J].
KAHN, RS ;
WETZLER, S .
BIOLOGICAL PSYCHIATRY, 1991, 30 (11) :1139-1166
[10]   ELECTROCARDIOGRAM CHANGES AND THERAPEUTIC DESIPRAMINE AND 2-HYDROXY-DESIPRAMINE CONCENTRATIONS IN ELDERLY DEPRESSIVES [J].
KUTCHER, SP ;
REID, K ;
DUBBIN, JD ;
SHULMAN, KI .
BRITISH JOURNAL OF PSYCHIATRY, 1986, 148 :676-679